MyoKardia soars 59% after Bristol-Myers agrees to acquire it for $13 billion in cash
MyoKardia's mavacamten candidate is expected to be submitted to the FDA for approval in the first quarter of 2021.
Full Article
MyoKardia soars 59% after Bristol-Myers agrees to acquire it for $13 billion in cash
Business Insider
0 shares
1 views
You might like
Related news coverage
Bristol Myers Snaps Up MyoKardia For $225/Share
Bristol Myers Squibb (BMY) has agreed to acquire MyoKardia Inc. (MYOK) for $13.1 billion, or $225.00 per share in cash.
RTTNews
Bristol to Pay $13.1 Billion for Heart-Drug Maker MyoKardia
Cancer-drug powerhouse Bristol Myers Squibb said it will buy biotech MyoKardia in a $13.1 billion all-cash deal aimed at expanding..
Upworthy